Page 5 - Briefing Document News Today

Message : Required fields Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased ChemoCentryx, Inc. (NASDAQ: CCXI) securities between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”). Investors have until July 6, 2021 to apply to the Court to be appointed as lead plaintiff in the law...

Share this article Share this article NEW YORK, July 1, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On May...

RADNOR, Pa., June 12, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class...

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI). Such...

/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming July 6, 2021 deadline to file a lead plaintiff motion in the class action...

/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against...

The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021, inclusive (the "Class Period").

Share this article Share this article NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On May...

RADNOR, Pa., May 31, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds ChemoCentryx, Inc. (NASDAQ: CCXI)...

/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against ChemoCentryx,...